Dendritic Cell Carriers for Systemic Oncolytic Virus Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using oncolytic viruses face inefficiencies in systemic delivery to tumors, high adverse effects, and unpredictable patient responses, with existing immune therapies being expensive and unreliable.
Innovation Solution
Utilizing dendritic cells as carriers to load and deliver oncolytic viruses systemically, enhancing delivery efficiency by forming complexes with neutralizing antibodies and targeting tumor sites, and administering multiple virus strains sequentially or simultaneously to overcome immune barriers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If oncolytic viruses are administered systemically to treat metastatic cancer, then the viruses can reach distant tumors and metastases, but the delivery efficiency is poor and the viruses fail to enter tumor bodies in sufficient quantities
Solution Approach 1:
The patent uses dendritic cells as intermediary carriers to transport oncolytic viruses through the bloodstream to tumor sites. The dendritic cells are engineered to express specific surface proteins that enable them to home to tumor locations, thereby mediating the delivery of viruses from the bloodstream to the tumor microenvironment, solving the problem of poor systemic delivery efficiency
Solution Approach 2:
The dendritic cells are engineered with autonomous navigation capabilities through the bloodstream, using expressed surface proteins to automatically home to tumor sites without external guidance. This self-service mechanism enables the carrier cells to independently locate and deliver viruses to the correct target, improving delivery efficiency while reducing the need for complex external targeting systems
2Reliability
If conventional chemotherapeutic and targeted drugs are used to treat cancer, then cancer cells can be targeted, but high incidence of severe adverse effects occurs
Solution Approach 1:
The patent employs oncolytic viruses that exhibit local quality by selectively replicating in and killing cancer cells while leaving normal cells unaffected. The viruses are engineered with tumor-specific replication properties, allowing them to concentrate their therapeutic effect locally at the tumor site without causing the systemic adverse effects associated with conventional chemotherapy
Solution Approach 2:
The patent converts the naturally lytic (cell-killing) property of viruses, which could be harmful, into a therapeutic benefit by engineering oncolytic viruses that selectively kill only cancer cells. The virus-induced cell lysis is transformed from a potentially harmful phenomenon into a controlled therapeutic mechanism that eliminates tumor cells while stimulating anti-tumor immunity
3Ease of operation
If current therapeutic protocols are used for advanced stage cancer with metastasis, then treatment can be provided, but substantial increase in 5-year patient survival is not achieved
Solution Approach 1:
The patent segments the therapeutic approach into multiple components: dendritic cell carriers for delivery, oncolytic viruses for direct tumor cell killing, and immune activation for systemic anti-tumor response. This segmentation allows each component to address specific aspects of metastatic cancer treatment, collectively improving survival rates while maintaining ease of administration through intravenous injection
4Quantity of substance
If dendritic cells are used as carriers for oncolytic viruses, then delivery efficiency to tumors increases, but the complexity of the treatment protocol increases
Solution Approach 1:
The dendritic cells are pre-engineered in vitro to express tumor-homing surface proteins before administration. This preliminary action of genetic modification in the laboratory allows the cells to autonomously navigate to tumors in vivo, simplifying the in vivo treatment protocol while maintaining high delivery efficiency. The complex engineering is performed beforehand, reducing the complexity of the actual treatment administration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Improves virus delivery to tumors, including across the blood-brain barrier, and increases therapeutic responses by avoiding neutralizing antibodies and resistant cancer cells, providing sustained remission and reduced side effects.
Implementation Method 1
dendritic cells as carriers for oncolytic viruses, loaded ex vivo and administered intravenously, which enhance delivery efficiency by protecting viruses from neutralizing antibodies and targeting them to tumor sites
Implementation Method 2
enhance delivery efficiency by protecting viruses from neutralizing antibodies
Implementation Method 3
initiate virus replication in the tumor microenvironment and the induction of tumor cell lysis induced by virus replication
Data Source
AI summary
A versatile carrier system for systemic delivery of oncolytic viruses comprises dendritic cells having at least one oncolytic virus loaded therein. It is believed that the dendritic cells will protect the oncolytic virus(es) against neutralizing antibodies, can transport the oncolytic virus(es) to targeted tumor locations, and then deliver virions to the tumor locations.